Published in Health Business Week, November 17th, 2006
The dispute involved Roche's Patent Portfolio for Polymerase Chain Reaction (PCR) and related technology.
Under the terms of the settlement, Ambry will pay Roche Diagnostics past royalties due in the field of Human In Vitro Diagnostics, and Roche Diagnostics has agreed to dismiss the arbitration proceedings it had initiated.
"Ambry acted in a completely responsible way after being advised of its obligations under our license agreement," said Melinda Griffith, senior VP and General Counsel at Roche Molecular Diagnostics, a business area of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.